[Line Items] for Description of Business

No definition available.

Name:	iep_DescriptionofBusinessLineItems
Namespace Prefix:	iep_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Aggregate Ownership interest of Parent and Holding Company Subsidiaries

+ References

No definition available.

+ Details

Name:	iep_LimitedLiabilityCompanyLlcOrLimitedPartnershipLpManagingMemberOrGeneralPartnerAggregateOwnershipInterestOfParentAndHoldingCompanySubsidiaries
Namespace Prefix:	iep_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of approved therapies.

+ References

No definition available.

+ Details

Name:	iep_NumberOfApprovedTherapies
Namespace Prefix:	iep_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of product candidate in active clinical development.

+ References

No definition available.

+ Details

Name:	iep_NumberOfProductCandidateInActiveClinicalDevelopment
Namespace Prefix:	iep_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The fair value of investment held in the subsidiary investment funds by the limited liability company or limited partnership.

+ References

No definition available.

+ Details

Name:	iep_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterestFairValue
Namespace Prefix:	iep_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Percentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

+ Details

Name:	us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).

+ References

+ Details

Name:	us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_OwnershipAxis=iep_IcahnEnterprisesHoldingsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iep_MembersOrPartnersAxis=iep_IcahnEnterprisesGPMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iep_MembersOrPartnersAxis=iep_PrincipalOwnersAndAffiliatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=iep_IcahnEnterprisesGPMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=iep_CvrRefiningLpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=iep_CvrEnergyIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=iep_EnergySegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=iep_ViskaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=iep_InvestmentFundsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=iep_CvrPartnersLpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=iep_VivusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=iep_PharmaSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Description of Business (Details) $ in Billions		3 Months Ended
Description of Business (Details) $ in Billions	Nov. 21, 2022	Mar. 31, 2023 USD ($) product item	Dec. 31, 2022 USD ($)
Icahn Enterprises Holdings
Description of Business [Line Items]
Percentage of equity ownership in operating subsidiary		99.00%
Icahn Enterprises Holdings \| Icahn Enterprises G.P.
Description of Business [Line Items]
General partner ownership percentage in Icahn Enterprises		1.00%
Icahn Enterprises Holdings \| Mr. Icahn and affiliates
Description of Business [Line Items]
Affiliate ownership interest		84.00%
Icahn Enterprises G.P.
Description of Business [Line Items]
Aggregate general partner ownership interest of parent and operating subsidiary		1.99%
CVR Refining
Description of Business [Line Items]
Percentage of equity ownership in operating subsidiary	37.00%	37.00%
CVR Energy \| Energy Segment
Description of Business [Line Items]
Percentage of equity ownership in operating subsidiary		71.00%
Viskase \| Private Placement
Description of Business [Line Items]
Percentage of equity ownership in operating subsidiary		90.00%
Investment Funds
Description of Business [Line Items]
Fair value of investment in subsidiary \| $		$ 4.0	$ 4.2
CVR Partners \| CVR Energy
Description of Business [Line Items]
Percentage of equity ownership in operating subsidiary		100.00%
Vivus \| Pharma Segment
Description of Business [Line Items]
Number Of Approved Therapies \| item		2
Number Of Product Candidate In Active Clinical Development \| product		1